April 22, 2024

A New York City Ethics Committee Embraces Litigation Funding

Subscribe to Our Newsletter

Newsletter


William Marra

|

April 22, 2024

The City Bar’s recommendation is significant because it represents yet another high-profile body rejecting the U.S Chamber of Commerce’s arguments regarding litigation funding, a guest columnist writes for the Law Journal.

A key New York City Bar Association ethics committee’s proposal that New York amend its legal ethics rules to explicitly permit litigation finance agreements between lawyers and funders could be a watershed moment for the litigation finance industry.

If the proposal is accepted, New York would become the latest—and the largest—jurisdiction to join a growing chorus of states that are amending their ethics rules to clarify that litigation funding is a permissible and welcome feature of our legal system. And if New York, the country’s largest legal market, were to lead on this issue, other jurisdictions would likely soon follow, creating a positive cascade effect for litigation funding and access-to-justice initiatives.

At issue is Rule 5.4 of the New York Rules of Professional Conduct, which says lawyers may not “share legal fees” with nonlawyers. The New York City Bar Association’s Professional Responsibility Committee  recommended  this month that New York amend Rule 5.4 to explicitly clarify that lawyers may assign their interest in fees to a nonlawyer, so long as the lawyer gives the client notice and opportunity to inquire prior to any such assignment.

The recommendation follows a growing trend across the nation. In 2020, Arizona’s Supreme Court abolished the state’s version of Rule 5.4 entirely for the  stated purpose  of “promot[ing] business innovation in providing legal services at affordable prices.” Around the same time, Utah’s Supreme Court created a “ regulatory sandbox ” that allows licensed lawyers to experiment with nonlawyer ownership. And Washington D.C.’s  Rule 5.4(b)  has long allowed certain forms of non-lawyer ownership of law firms.

In one sense, the City Bar committee’s recommendation is unremarkable. As I have recently  explained , New York courts have repeatedly reaffirmed the legality, propriety, and benefits of litigation funding.  Two   separate  state court judges have written opinions stating that third-party funding allows “lawsuits to be decided on their merits, and not based on which party has deeper pockets or stronger appetite for protracted litigation.” The City Bar committee likewise emphasized that “there is now a long history of court decisions enforcing” lawyer-funder agreements.

Yet in other ways, the committee’s recommendation could be a crucial domino.This is because some critics of litigation funding still invoke Rule 5.4 to charge that funders create conflicts of interest and meddle with attorney-client independence. Most notably, the U.S. Chamber of Commerce’s Institute for Legal Reform recently released a  report  claiming that efforts to pare back Rule 5.4 would “significantly decrease the quality of legal representation” including by “creating inevitable conflicts of interest among lawyers [and] clients” and by “making the settlement of lawsuits more difficult, inefficient, and expensive.”

The chamber has the explicit goal of curtailing litigation finance, a tool that helps cash-poor litigants pay their lawyers and win their cases.

The City Bar’s recommendation is significant because it represents yet another high-profile body rejecting the chamber’s arguments. Indeed, the committee dismissed as ill-conceived “paternalism” the suggestion that “one type of financing has the power to corrupt a lawyer’s professional ethics more than any other financial arrangement with a nonlawyer.”

The history here is especially remarkable, for in  July 2018, the City Bar’s professional ethics committee issued a controversial  opinion  suggesting that litigation funding agreements between funders and law firms might violate Rule 5.4. That opinion caused a stir, leading the association to convene a working group that  effectively repudiated  the 2018 ethics opinion and called for amendments to Rule 5.4. And now, a separate committee of the City Bar has itself proposed amendments, which will be sent to the New York State Bar Association, and ultimately New York’s appellate courts, for approval.

Of course, even without widespread amendments of Rule 5.4, the litigation funding industry is fast becoming a mainstay of our civil justice system. A recent  survey  by Westfleet Advisors, a litigation finance consultancy, found that $2.7 billion was committed to new deals last year, with two-thirds of funding agreements occurring between funders and law firms. (Rule 5.4’s ambit is limited to agreements between funders and  law firms ; no one argues that agreements between funders and  claimholders  implicate Rule 5.4.)

Nevertheless, more explicit approval would further dispel any doubts about the propriety of litigation funding. This would invite more law firms to accept third-party capital that can help the firms innovate and offer better, more affordable legal services to their clients, bringing the transformative power of the capital markets to one of its last redoubts in America, the legal industry.

This should in turn increase access to the courts and make our legal system more rather than less efficient, as both New York City’s professional responsibility committee and the Arizona Supreme Court have recognized.

Indeed, it is no coincidence that litigation funding is going mainstream, and efforts to modify and repeal Rule 5.4 are gaining steam, as a growing body of  scholarship  is concluding (contrary to the Chamber’s assertions) that litigation funding expedites case resolution, reduces litigation spend, and lowers the cost of legal services.

Consider, for example, the claim that litigation funding promotes frivolous litigation. Funders typically invest in 5% or less of the opportunities—only the  strongest  claims—because funders that back weak cases will soon go out of business. Indeed, there is a growing recognition that funding more likely  deters  weak cases, because funders effectively screen meritless cases from ever getting filed in the first place. After all, if two or three litigation funders refuse to fund your case, will you want to invest your own resources into the matter? Probably not.

The City Bar committee’s recommendation is a welcome and potentially watershed step towards increasing acceptance of litigation funding – which should in turn increase meritorious litigants’ access to the courts.

***

William Marra  is a director at Certum Group, where he leads the litigation finance strategy, and a lecturer at the University of Pennsylvania Carey School of Law, where he co-teaches a course on litigation finance.

***

Reprinted with permission from the April 17, 2024 edition of the New York Law Journal © 2024 ALM Global Properties, LLC. All rights reserved. Further duplication without permission is prohibited, contact 877-256-2472 or  asset-and-logo-licensing@alm.com.

Certum Group Can Help

Get in touch to start discussing options.

Recent Content

By Certum Group February 24, 2026
Columbia Law School’s blog on corporations and the public markets, The CLS Blue Sky Blog, recently featured the scholarly work on litigation finance written by Indiana University Business School Professor Suneal Bedi and Certum’s William C. Marra. In their blog post, Bedi and Marra discuss their article Litigation Finance in the Market Square , which was recently published in the Southern California Law Review. Their work reframes litigation finance as a capital markets innovation rather than solely a civil justice mechanism. While much of the public debate has centered on questions of disclosure, control, and settlement incentives, Bedi and Marra emphasize that legal claims often represent significant but illiquid contingent assets on a firm’s balance sheet. When policymakers regulate litigation finance, they are regulating not just the legal business but the capital markets. And they are regulating capital markets in a way that is more likely to harm small and medium-sized enterprises (SMEs) while protecting large companies from competition.  The full blog post is available here.
By William C. Marra February 18, 2026
You signed an NDA and shared case materials with your funder. Then you negotiated and signed a term sheet . Now it’s time to negotiate the litigation funding agreements. Funding agreements sit at the intersection of law, finance, and business. They’re not equity transactions, and they’re not debt transactions either. For most people, they’re new: Most funded parties we encounter—even the most experienced operators—have never before negotiated or signed a funding agreement. Here are some tips as you navigate the funding agreement process. Make Sure the Funding Agreement Tracks the Term Sheet The term sheet sets the commercial deal, but the funding agreement is the binding contract. The funding agreement should accurately reflect the economics and key terms you agreed to. Pay close attention to ensure the return structure, waterfall, and budget closely track what was agreed to in the term sheet. Small deviations from the term sheet can have big economic consequences. Confirm that the final agreement memorializes the deal you negotiated. Control and Decision-Making Litigation funders do not control litigation strategy or settlement decisions. Some court rules, including those in the District of New Jersey , request a disclosure that a funder’s approval is not necessary for case strategy or settlement. Certum’s contracts expressly disclaim control. Consider whether an express disclaimer of control, frequently tracking the language of the District of New Jersey rule, is appropriate. As repeat players in the litigation space , litigation funders can and do still provide valuable advice to funded parties, who are often involved in their first and only litigation. Thus although funders cannot control litigation, funded parties typically consult with funders for advice during the course of the litigation. Define “Case Proceeds” Clearly Litigation funding agreements are typically non-recourse, which means the funder recovers only if there are case proceeds. So the definition of “case proceeds” is quite important, and it’s something you should pay close attention to. Cash recoveries are straightforward, but not all litigations resolve solely or exclusively for cash. What happens if there is a non-cash settlement—for example, if the funded party receives stock, real estate, IP rights? What happens if the settlement is structured as a payment over time? Or if there is a sanctions award entered against the defendant? It’s best to address all these issues ex ante at the time of the funding agreement. Funding agreements typically provide a mechanism for valuing consideration other than an immediate payment of cash from the defendant to the plaintiff. Resolving this issue today can help avoid ambiguity tomorrow. Address Other Customary Provisions Several boilerplate provisions deserve attention: Representations and warranties: As with all financial transactions, the recipient of funds needs to provide certain customary representations and warranties. Make sure you study those reps and warranties, to ensure you can stand behind them. Termination rights: When can the funder withdraw? Funders typically have termination rights, for example in instances where the funded party commits a material breach of the agreement. Make sure you understand the consequences of a termination. Consider Hiring Experienced Deal Counsel Litigation funding agreements are specialized contracts. They combine elements of finance, litigation, and insurance. Most generalist lawyers—and even many litigators—have never negotiated one. Certum typically recommends that funded parties retain an independent deal counsel who understands the funding market. Experienced advisors can streamline the process and increase the likelihood that the deal will close. And you can typically negotiate with the funder to have the deal counsel’s fees covered as a closing cost of the investment.
By Tyler Perry February 11, 2026
When Americans think about civil litigation, we tend to imagine its bilateral form: Company A sues Company B, or John Roe sues Jane Doe. That model works when disputes are discrete, parties are evenly matched, and harms are easily traced. It breaks down, however, when injuries are widespread, claims are too small to justify individual pursuit, and thousands of plaintiffs confront a single, well-resourced defendant. Those conditions gave rise to what we now call mass actions—procedural mechanisms that aggregate claims without extinguishing individual rights. This post traces the evolution of American mass actions from their equitable origins, through Rule 23 class actions, to the modern dominance of multidistrict litigation (“MDL”). Its purpose is to explain how, across each stage of its development, the system moved and evolved in order to tackle the same core problem: how to capture the efficiencies of collective adjudication while preserving individualized justice. The Equitable Origins of Mass Actions For roughly the first 150 years of American civil practice, what we would now recognize as class actions existed in equity, borrowing from English Chancery traditions. Former Equity Rule 48 permitted representative litigation where a common or general interest affected a class so numerous that joinder was impracticable. Courts used these bills in equity to cluster related claims, creating an early—if imperfect—form of aggregation. These tools, however, were ill-suited to large-scale disputes. Among other things, they offered no uniform standard for representation, limited mechanisms for managing individualized issues, and little guidance for balancing efficiency against fairness, including whether absent parties would be bound. As collective harms grew larger and more complex, these limitations became more pronounced. The Adoption of Rule 23 and the Birth of the Class Action The adoption of Federal Rule of Civil Procedure 23 in 1938 marked a turning point. Rule 23 replaced ad hoc equitable practices with a codified framework defining when a small number of plaintiffs could litigate on behalf of many. Rule 23 introduced a new codified framework in 1938, later refined by the 1966 amendments into today’s familiar certification requirements—numerosity, commonality, typicality, adequacy, predominance, and superiority—meant to ensure that aggregation serves both efficiency and fairness. Rule 23 works best where common questions truly drive the case. But as mass disputes expanded—particularly in products liability and antitrust—its limitations became apparent. Variations in exposure, injury, causation, damages, and governing law strain the class model. Under Rule 23(b)(3), courts certify a class only if common questions predominate—a demanding standard that frequently defeats certification in mass torts. Beyond doctrine, this mismatch raises fairness and due-process concerns, as aggregation risks resolving individualized questions of liability and damages through procedural shortcuts ill-suited to protect either side’s substantive rights. The Creation of the JPML and the Rise of the MDL Congress responded in 1968 by creating the Judicial Panel on Multidistrict Litigation. That structure authorizes transfer of civil actions with common factual questions to a single federal court for coordinated pretrial proceedings. Unlike class actions, MDLs preserve the separateness of each plaintiff’s case while centralizing work that benefits from scale, including motions to dismiss, summary judgment, and Daubert proceedings. In practice, transferee judges appoint leadership counsel, coordinate discovery, resolve common dispositive and evidentiary motions, conduct bellwether trials, and facilitate global settlement discussions. The MDL’s central innovation is procedural coordination without substantive consolidation. Each plaintiff formally retains an individual claim, remedy, and trial right, while the system avoids duplicative rulings and inconsistent outcomes and preserves Article III adjudication of individual disputes. Amchem, Ortiz , and the Limits of Settlement-Only Class Actions Supreme Court decisions in Amchem Products, Inc. v. Windsor and Ortiz v. Fibreboard Corp. sharply limited the availability of settlement-only mass tort class actions . The Court held that Rule 23’s requirements apply with full force even when certification is sought solely to effect a global settlement, emphasizing rigorous scrutiny of adequacy, predominance, and intra-class conflicts in heterogeneous litigations. In other words, settlement convenience could not cure structural mismatches between the class device and the individualized nature of mass tort claims. These decisions did not eliminate class actions. But they underscored why mass torts rarely fit comfortably within them—and why MDLs emerged as the system’s primary alternative. Their practical import was to effectively close the door to using Rule 23 as a vehicle for mandatory, one-shot global peace in tort, channeling resolution toward MDL-based private ordering—bellwethers, negotiated matrices, and opt-in inventory settlements—while preserving each plaintiff’s trial right. They also shifted innovation elsewhere: toward issue classes under Rule 23(c)(4) , parens patriae actions by sovereigns, and, in some instances, bankruptcy or “Texas two-step” strategies to obtain non-class global resolutions—developments that further entrenched the MDL as the central forum for mass tort resolution. Why MDL Endures MDL’s durability reflects institutional alignment rather than doctrinal accident. For plaintiffs, MDLs offer scale—shared discovery, coordinated motion practice, and settlement leverage—without forfeiting individual claims or trial rights. For defendants, they provide predictability and efficiency by centralizing pretrial proceedings, reducing duplicative costs, and mitigating inconsistent rulings across jurisdictions. For courts, MDLs conserve scarce judicial resources while preserving adjudicatory limits by restricting consolidation to the pretrial phase. For the justice system, MDLs supply a flexible framework that absorbs heterogeneity without collapsing into either unmanageable fragmentation or overinclusive aggregation. That convergence explains why the MDL has become the default architecture for modern mass tort litigation—and why it has proven resilient despite critique. The Design Challenge That Endures Modern practice selects among procedural tools based on fit. Class actions remain essential where common issues predominate. MDLs dominate where common facts justify coordination but individualized harms demand separation. Together, these mechanisms keep the civil justice system workable—and meaningful—when harms scale beyond the individual case. The enduring challenge is deploying these tools with discipline, judiciously retaining the benefits of individual justice, while capitalizing on the benefits of aggregation.